Jørgensen Karsten Juhl, Klahn Anders, Gøtzsche Peter C
The Nordic Cochrane Centre, Rigshospitalet, Blegdamsvej 9, Copenhagen, Denmark.
BMC Med. 2007 May 30;5:12. doi: 10.1186/1741-7015-5-12.
The CONSORT statement specifies the need for a balanced presentation of both benefits and harms of medical interventions in trial reports. However, invitations to screening and newspaper articles often emphasize benefits and downplay or omit harms, and it is known that scientific articles can be influenced by conflicts of interest. We wanted to determine if a similar imbalance occurs in scientific articles on mammography screening and if it is related to author affiliation.
We searched PubMed in April 2005 for articles on mammography screening that mentioned a benefit or a harm and that were published in 2004 in English. Data extraction was performed by three independent investigators, two unblinded and one blinded for article contents, and author names and affiliation, as appropriate. The extracted data were compared and discrepancies resolved by two investigators in a combined analysis. We defined three groups of authors: (1) authors in specialties unrelated to mammography screening, (2) authors in screening-affiliated specialties (radiology or breast cancer surgery) who were not working with screening, or authors funded by cancer charities, and (3) authors (at least one) working directly with mammography screening programmes. We used a data extraction sheet with 17 items described as important benefits and harms in the 2002 WHO/IARC-report on breast cancer screening.
We identified 854 articles, and 143 were eligible for the study. Most were original research. Benefits were mentioned more often than harms (96% vs 62%, P < 0.001). Fifty-five (38%) articles mentioned only benefits, whereas seven (5%) mentioned only harms (P < 0.001). Overdiagnosis was mentioned in 35 articles (24%), but was more often downplayed or rejected in articles that had authors working with screening, (6/15; 40%) compared with authors affiliated by specialty or funding (1/6; 17%), or authors unrelated with screening (1/14; 7%) (P = 0.03). Benefits in terms of reduced breast cancer mortality were mentioned in 109 (76%) articles, and was more often provided as a relative risk reduction than an absolute risk reduction, where quantified (45 articles (31%) versus 6 articles (3%) (P < 0.001)).
Scientific articles tend to emphasize the major benefits of mammography screening over its major harms. This imbalance is related to the authors' affiliation.
CONSORT声明规定,试验报告中需要平衡呈现医学干预措施的益处和危害。然而,筛查邀请和报纸文章往往强调益处,而淡化或忽略危害,并且已知科学文章可能会受到利益冲突的影响。我们想确定在关于乳腺钼靶筛查的科学文章中是否也存在类似的失衡情况,以及这是否与作者所属机构有关。
2005年4月,我们在PubMed上搜索了2004年发表的、提及乳腺钼靶筛查益处或危害的英文文章。数据提取由三名独立研究人员进行,两名不设盲,一名对文章内容、作者姓名及所属机构设盲(视情况而定)。提取的数据由两名研究人员在综合分析中进行比较并解决差异。我们将作者分为三组:(1)与乳腺钼靶筛查无关专业的作者;(2)筛查相关专业(放射学或乳腺癌手术)中不从事筛查工作的作者,或由癌症慈善机构资助的作者;(3)直接参与乳腺钼靶筛查项目的作者(至少一名)。我们使用了一份数据提取表,其中包含2002年世界卫生组织/国际癌症研究机构关于乳腺癌筛查报告中描述为重要益处和危害的17项内容。
我们识别出854篇文章,其中143篇符合研究条件。大多数是原创研究。提及益处的文章比提及危害的文章更多(96%对62%,P<0.001)。55篇(38%)文章仅提及益处,而7篇(5%)文章仅提及危害(P<0.001)。35篇文章(24%)提到了过度诊断,但在有从事筛查工作作者的文章中,过度诊断更常被淡化或否定(6/15;40%),相比之下,专业相关或资助相关作者的文章(1/6;17%)以及与筛查无关作者的文章(1/14;7%)(P = 0.03)。109篇(76%)文章提到了乳腺钼靶筛查在降低乳腺癌死亡率方面的益处,在进行量化时,以相对风险降低而非绝对风险降低的形式呈现益处的情况更常见(45篇文章(31%)对6篇文章(3%)(P<0.001))。
科学文章往往更强调乳腺钼靶筛查的主要益处而非主要危害。这种失衡与作者所属机构有关。